In a study published in AIDS Research and Therapy, Ph.D. candidate Thinh Vu explores the temporal trends in the time from HIV diagnosis to the initiation of antiretroviral therapy (ART) across the ...

Switching to islatravir and doravirine was just as effective as bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of ...

Merck (MRK) announced the presentation of “positive” results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

North America was the major shareholder in 2022. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period. PO ...

However, owing to the limited pharmacokinetics and biodistribution of HIV antiretroviral drugs, sanctuary sites develop where the virus can persist. This not only makes eradication of the virus ...

Background: Poor adherence to antiretroviral therapy (ART ... challenge to achieving optimal health outcomes for children living with HIV, leading to virologic failure, drug resistance, and increased ...

A groundbreaking injectable that would curb the spread of HIV is at risk due to Donald Trump's funding cuts on foreign aid. A groundbreaking injectable designed to curb the global spread of HIV is ...

There's an arms race in medicine -- scientists design drugs to treat lethal bacterial infections, but bacteria can evolve defenses to those drugs, sending the researchers back to square one.

AZT was the first antiretroviral medication used to prevent and treat HIV/AIDS, but according to Harrelson, it was a 'really ineffective' and dangerous drug that killed people, including his ...